The race for the tiniest waist just got even more competitive.
New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.
The findings suggest the newcomer could one day outperform some of the biggest names in the booming GLP-1 market, including Wegovy and Mounjaro.
In the 48-week trial, researchers from Fudan University in Shanghai recruited 567 adults who were overweight or obese and divided them into four groups.
Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams or 6 milligrams, while the fourth received a placebo.
Behind the experimental drug is Chinese pharmaceutical giant Hengrui, which partnered with US biotech firm Kailera Therapeutics to bring ribupatide to markets outside China.
Ribupatide works by mimicking two hormones naturally produced in the gut that help regulate appetite, digestion and blood sugar.
It’s a similar approach to that used by Eli Lilly’s blockbuster drugs Mounjaro and Zepbound. But ribupatide has been designed to bind more tightly to its targets and stay active in the body longer, potentially extending its effects throughout the week.
Everyone in the study — including those given placebo shots — also followed a lifestyle program that included dietary counseling and recommendations to get at least 150 minutes of moderate exercise each week.
After 48 weeks, those taking the lowest dose of ribupatide had lost an average of 10.7% of their starting body weight. Those on the 4-milligram dose shed 16.4%, while participants taking the highest dose lost a whopping 17.7%.
The placebo group lost just 1.4%.
The numbers are in the same ballpark as — and potentially higher than — those seen with Wegovy. In a separate clinical trial, people taking a 2.4 mg dose of the popular GLP-1 shot lost an average of 14.9% of their body weight over a longer period of 68 weeks.
And ribupatide’s results could have been even more impressive. Weight loss hadn’t started to level off among participants taking the two highest doses by the end of the 11-month study, suggesting they could have lost even more with longer treatment.
And the benefits extended beyond the scale.
Although none of the participants had diabetes, researchers found that those taking ribupatide had reductions in blood sugar. They also saw improvements in blood pressure and cholesterol.
Their waistlines shrank, too — an important measurement because abdominal fat is linked to an increased risk of heart disease and other health problems.
The participants taking ribupatide saw their waist measurements drop by between 9 and 14 centimeters, compared with just 2.5 centimeters among those on the placebo.
The drug wasn’t without some familiar side effects, though. Like other GLP-1s, ribupatide most commonly caused digestive problems, including nausea, vomiting and diarrhea. The researchers said the symptoms were generally mild to moderate and occurred most often as participants increased their doses.
Study authors said their results are promising and come amid a need for more pharmacological treatment options as obesity continues to plague millions of people.
The problem is particularly acute in the US, where roughly four in 10 adults have obesity and an even larger share are overweight. Among children and teenagers ages 2 to 19, just over 21% have obesity.
It’s no wonder Americans’ appetite for weight-loss injections shows little sign of slowing. A September Gallup survey found that 11% of US adults were currently taking a GLP-1 medication for weight loss, up from just 3% in 2024.
Overall, 15% said they had taken one of the blockbuster drugs at some point in their lives — a jump of nine percentage points in just two years.
